The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...
PORTLAND, Ore. (KOIN) — A recall has been issued for insulin pens from one manufacturer because they may not have labels on the injectors, the Food and Drug Administration said in a press release ...
The state’s CalRx Insulin Glargine will be available to consumers for a suggested retail price of $55 or less per five-pack of pens beginning Jan. 1, 2026. The insulin glargine pen agreement with ...
Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...
Please provide your email address to receive an email when new articles are posted on . Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection ...
Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons of five. Some pens might be missing their labels. In ...
The recalled product does not pertain to the branded interchangeable biosimilar, Semglee (insulin glargine-yfgn). Mylan Pharmaceuticals has voluntarily recalled 1 batch of Insulin Glargine (insulin ...
Semglee and Insulin Glargine may now be substituted for the reference product Lantus (insulin glargine) at the pharmacy counter. Viatris Inc. and Biocon Biologics have announced the launch of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results